AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11253475 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived microparticles measured on the 3rd (13.0 +/‐ 3.0%) day after stroke onset
Number of subjects: 50
Study 8616303 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated margarine
Number of subjects: 49
Study 8616303 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 49
Study 1600261 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36
Study 1600261 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 36
Study 1600261 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Enalapril vs Trichlormethiazide
Number of subjects: 36
Study 3903787 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (0.6 g per day)
Number of subjects: 20
Study 3903787 — intervention group
Group type: EXPERIMENTAL
Intervention: Triletide (2 g per day)
Number of subjects: 20
Study 30736704 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective mental contrasting condition
Number of subjects: 110
Study 30736704 — intervention group
Group type: COMPARATOR
Intervention: Instrumental mental contrasting condition
Number of subjects: 110
Study 30736704 — intervention group
Group type: COMPARATOR
Intervention: Standard mental contrasting intervention
Number of subjects: 110
Study 30007401 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm lunch meal with a variety of vegetables, 3 days a week for 3 months
Number of subjects: 210
Study 30007401 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm lunch meal with a variety of vegetables + pedagogical tools (sensory lessons, meal practice advice)
Number of subjects: 210
Study 30007401 — intervention group
Group type: COMPARATOR
Intervention: Usual meal practices
Number of subjects: 210
Study 26359711 — intervention group
Group type: EXPERIMENTAL
Intervention: TY-51924
Number of subjects: 105
Study 26359711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 25226857 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) - IUI for group 2A (FSH 10-15 mIU/mL and E2<40 pg/mL)
Number of subjects: 603
Study 25226857 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) - IUI for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Number of subjects: 603
Study 25226857 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)
Number of subjects: 603
Study 25226857 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal FSH of 10-15 mIU/mL and E2≥40 pg/mL
Number of subjects: 603
Study 23756586 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (56 g of walnuts daily)
Number of subjects: 46
Study 23756586 — intervention group
Group type: COMPARATOR
Intervention: Control diet without walnuts
Number of subjects: 46
Study 23756586 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet
Number of subjects: 46
Study 19834690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingually (2 mg)
Number of subjects: 15
Study 19834690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine subcutaneously (0.005 mg/kg)
Number of subjects: 15
Study 19834690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (subcutaneously)
Number of subjects: 15
Study 19834690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17654304 — intervention group
Group type: EXPERIMENTAL
Intervention: INS50589 (0.1-3 mg/kg/h for four hours)
Number of subjects: 36
Study 17654304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16029400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 22
Study 16029400 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-remifentanil
Number of subjects: 22
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine users of aspirin
Number of subjects: 19283
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine users of warfarin
Number of subjects: 19283
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued aspirin use
Number of subjects: 19283
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued warfarin use
Number of subjects: 19283
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine continuous users of aspirin
Number of subjects: 19283
Study 13129878 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine continuous users of warfarin
Number of subjects: 19283
Study 10383509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d.
Number of subjects: 122
Study 10383509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 8867868 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial TD
Number of subjects: 266
Study 8867868 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbtruncal TD
Number of subjects: 266
Study 8867868 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical dyskinesia
Number of subjects: 266
Study 8867868 — intervention group
Group type: EXPERIMENTAL
Intervention: History of alcohol abuse or dependence
Number of subjects: 266
Study 8867868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremor
Number of subjects: 266
Study 2066053 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (500 mg t.i.d.)
Number of subjects: 40
Study 2066053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6316289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole treatment (daily doses ranged from 3 to 13 mg/Kg, treatment period from 7 days to 14 months)
Number of subjects: 21
Study 29374667 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusion
Number of subjects: 150
Study 29374667 — intervention group
Group type: COMPARATOR
Intervention: No epidural infusion
Number of subjects: 150
Study 27253224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) alone or in combination with chemo- and/or radiotherapy
Number of subjects: 9
Study 27253224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 9
Study 24902456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl
Number of subjects: 96
Study 24902456 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 96
Study 24902456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 96
Study 24902456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (in both propofol plus fentanyl and midazolam plus fentanyl groups)
Number of subjects: 96
Study 22361918 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 71
Study 22361918 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 71
Study 20427750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 98
Study 20427750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 18657674 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice cardiac MDCT
Number of subjects: 268
Study 18657674 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic strategy
Number of subjects: 268
Study 16248236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maiwei Dihuang Oral Liquid (MDOL) 10 ml twice daily for 3 months
Number of subjects: 60
Study 16248236 — intervention group
Group type: COMPARATOR
Intervention: Prednisone initial dose of 0.5-1 mg/kg, reduced conditionally over 6-8 weeks
Number of subjects: 60
Study 12842525 — intervention group
Group type: EXPERIMENTAL
Intervention: ENOX < 12
Number of subjects: 161
Study 12842525 — intervention group
Group type: COMPARATOR
Intervention: ENOX
Number of subjects: 161
Study 10971320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%/tretinoin 0.025% gel (CTG; Velac) applied once daily
Number of subjects: 100
Study 10971320 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 1% lotion (CLN; Dalacin T) applied twice daily
Number of subjects: 100
Study 8842578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 8842578 — intervention group
Group type: EXPERIMENTAL
Intervention: Written examination
Number of subjects: 0
Study 8842578 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure (sauna at 66 degrees C for 40 min)
Number of subjects: 0
Study 8842578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (4 degrees C for 40 min)
Number of subjects: 0
Study 8842578 — intervention group
Group type: COMPARATOR
Intervention: Control levels (baseline)
Number of subjects: 0
Study 1518664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (7-day administration)
Number of subjects: 0
Study 1518664 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (7-day administration)
Number of subjects: 0
Study 6481665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic time-limited groups
Number of subjects: 24
Study 31163241 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study 31163241 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 97
Study 31163241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 31645451 — intervention group
Group type: EXPERIMENTAL
Intervention: etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody, single systemic administration
Number of subjects: 12
Study 31645451 — intervention group
Group type: EXPERIMENTAL
Intervention: etokimab (ANB020)
Number of subjects: 12
Study 29798192 — intervention group
Group type: EXPERIMENTAL
Intervention: APP (application) used in addition to standard discharge instruction
Number of subjects: 144
Study 29798192 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instruction
Number of subjects: 144
Study 25466666 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 69
Study 25466666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23839157 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated RIX4414 human rotavirus vaccine
Number of subjects: 112
Study 23839157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 23839157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccinees and placebo recipients
Number of subjects: 112
Study 21145269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endovascular aortic aneurysm repair (EVAR)
Number of subjects: 360
Study 21145269 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 360
Study 18650162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 18650162 — intervention group
Group type: COMPARATOR
Intervention: Observation/no adjuvant chemotherapy
Number of subjects: 0
Study 16569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyc‐o‐Mato (5.7 mg of lycopene, 3.7 mg of phytoene, 2.7 mg of phytofluene, 1 mg of beta‐carotene, and 1.8 mg of alpha‐tocopherol)
Number of subjects: 26
Study 16569044 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (same taste and flavor, but devoid of active compounds)
Number of subjects: 26
Study 12518122 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate patch (15 mg)
Number of subjects: 144
Study 12518122 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (control group)
Number of subjects: 144
Study 11144400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg twice daily or 14 mg/kg once daily for 10 days or 7 mg/kg twice daily for 5 days
Number of subjects: 1274
Study 11144400 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 10 mg/kg 4 times daily for 10 days
Number of subjects: 1274
Study 9301496 — intervention group
Group type: COMPARATOR
Intervention: RBC 400 mg twice daily alone (RBC400)
Number of subjects: 232
Study 9301496 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC400+CLAR)
Number of subjects: 232
Study 9301496 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 800 mg twice daily co‐prescribed with clarithromycin 250 mg four times daily for 14 days (RBC800+CLAR)
Number of subjects: 232
Study 8472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules (3 sachets daily for 8 weeks)
Number of subjects: 20
Study 8472526 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide-dimeticone combination (3 sachets daily for 8 weeks)
Number of subjects: 20
Study 8472526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride effervescent granules
Number of subjects: 20
Study 8472526 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide-dimeticone combination
Number of subjects: 20
Study 3464876 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal, naproxen, sulindac (short acting NSAIDs)
Number of subjects: 0
Study 3464876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 3464876 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (long acting NSAID)
Number of subjects: 0
Study 28195977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Grip (FG) training
Number of subjects: 10
Study 28195977 — intervention group
Group type: COMPARATOR
Intervention: Normal diameter grip (CON) training
Number of subjects: 10
Study 27537687 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Support Lifestyle Modification (GSLiM)
Number of subjects: 194
Study 27537687 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling
Number of subjects: 194
Study 24430917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols (maximum daily dose, 86.4 mg of Δ9‐tetrahydrocannabinol and 80 mg of cannabidiol)
Number of subjects: 51
Study 24430917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 51
Study 24430917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 22866361 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive nursing intervention including BP education sessions, monitoring, goal setting, and reinforcement over 12 weeks with a 30-day follow-up.
Number of subjects: 118
Study 22866361 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 118
Study 20515208 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus CBT-GSH
Number of subjects: 123
Study 20515208 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 123
Study 18448601 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth delivery of the Lidcombe Program of Early Stuttering Intervention
Number of subjects: 0
Study 18448601 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 16416357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure (mean PbB 5.4 microg Pb/100 ml)
Number of subjects: 48
Study 16416357 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean PbB 4.7 microg Pb/100 ml)
Number of subjects: 48
Study 16416357 — intervention group
Group type: EXPERIMENTAL
Intervention: High cumulative lead exposure (IBL, >5000; duration of exposure, >5 years)
Number of subjects: 48
Study 16416357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead exposure (current and cumulative measurements)
Number of subjects: 48
Study 12391100 — intervention group
Group type: EXPERIMENTAL
Intervention: (13)C‐enriched 6% CHO(exo) beverage (total volume per trial: 24 ml/kg)
Number of subjects: 22
Study 12391100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12391100 — intervention group
Group type: EXPERIMENTAL
Intervention: (13)C‐enriched 6% CHO(exo) beverage
Number of subjects: 22
Study 10571596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral plus topical mesalazine (2.4 g/day oral + 4 g/day topical)
Number of subjects: 22
Study 10571596 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine (2.4 g/day)
Number of subjects: 22
Study 8687366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (group treatment)
Number of subjects: 50
Study 8687366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by exposure in vivo (group treatment)
Number of subjects: 50
Study 8687366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (integrated from the start, group treatment)
Number of subjects: 50
Study 8687366 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatments
Number of subjects: 50
Study 2065622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) solution
Number of subjects: 60
Study 7027746 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg b.i.d.
Number of subjects: 106
Study 7027746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 29669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification with adjunctive endocapsular nuclear fragmentation using a manual microinterventional nitinol filament loop device (miLOOP)
Number of subjects: 101
Study 29669780 — intervention group
Group type: COMPARATOR
Intervention: Torsional phacoemulsification alone (controls)
Number of subjects: 101
Study 29669780 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification with miLOOP
Number of subjects: 101
Study 28728606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (1200 mg/day)
Number of subjects: 119
Study 28728606 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg/day)
Number of subjects: 119
Study 24860124 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin (Gelofusine, GEL group, n = 40)
Number of subjects: 80
Study 24860124 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐2 units FFP (FFP group, n = 40)
Number of subjects: 80
Study 23832729 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cans per day
Number of subjects: 27
Study 23832729 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cans per day
Number of subjects: 27
Study 16955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Case 1a (female patient with mild cognitive impairment)
Number of subjects: 122
Study 16955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Case 1b (male patient with mild cognitive impairment)
Number of subjects: 122
Study 16955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Case 2a (vascular dementia)
Number of subjects: 122
Study 16955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Case 2b (Alzheimer's disease)
Number of subjects: 122
Study 16955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interest in geriatric (psychiatric) topics
Number of subjects: 122
Study 14986193 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 15
Study 11672492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (4 sessions)
Number of subjects: 64
Study 11672492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (2 sessions)
Number of subjects: 64
Study 11672492 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (control condition)
Number of subjects: 64
Study 9423999 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 10 Gy treatment
Number of subjects: 280
Study 9423999 — intervention group
Group type: COMPARATOR
Intervention: 22.5 Gy in five daily fractions
Number of subjects: 280
Study 8237259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 394
Study 8237259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 394
Study 3541803 — intervention group
Group type: EXPERIMENTAL
Intervention: D + M (400 mg of doxycycline + 1500 mg of metronidazole)
Number of subjects: 261
Study 3541803 — intervention group
Group type: COMPARATOR
Intervention: D (400 mg of doxycycline)
Number of subjects: 261
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg
Number of subjects: 66
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 66
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Number of subjects: 66
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 40 mg
Number of subjects: 66
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 50 mg
Number of subjects: 66
Study 11388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (various doses)
Number of subjects: 66
Study 30643223 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture-modified foods and thickened drinks diet (nectar or pudding viscosity, controlled bolus volume) for 12 weeks
Number of subjects: 40
Study 30643223 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard treatment for 12 weeks
Number of subjects: 40
Study 29480843 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 86
Study 29480843 — intervention group
Group type: COMPARATOR
Intervention: Routine primary therapy (Control)
Number of subjects: 86
Study 26878772 — intervention group
Group type: EXPERIMENTAL
Intervention: specific amino acid mixture with micronutrients
Number of subjects: 32
Study 26878772 — intervention group
Group type: EXPERIMENTAL
Intervention: psychological neurological questionnaire (PNF)
Number of subjects: 32
Study 24465570 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine)
Number of subjects: 600
Study 22228773 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate/pravastatin 160/40 mg plus ezetimibe 10 mg (triple therapy)
Number of subjects: 273
Study 22228773 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg plus ezetimibe 10 mg (dual therapy)
Number of subjects: 273
Study 20435707 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 249
Study 17688170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate iontophoresis
Number of subjects: 20
Study 17688170 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study 16276320 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft disposable contact lenses (SCL), Biomedics 55 2-week disposable lenses, worn during waking hours.
Number of subjects: 81